Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation.
Level 5 - mechanism / opinion, no new human data
Narrative educational review synthesizing expert guidance without systematic search methodology or new primary data.
PubMed 36485151 · doi:10.1182/hematology.2022000401
What was done
This is a narrative educational review describing anticoagulant therapy management in women, focusing on diagnosis and management of abnormal or heavy menstrual bleeding (HMB), anticoagulation choices during pregnancy, and safety during lactation.
What was found
Up to 70% of anticoagulated menstruating individuals experience abnormal or heavy menstrual bleeding (HMB), often leading to iron deficiency (ferritin <50 ng/mL) with or without anemia. Rivaroxaban appears to have higher HMB rates than apixaban, dabigatran, or warfarin. HMB can be managed with combined hormonal contraceptives (CHCs) or depot-medroxyprogesterone acetate (DMPA) during therapeutic anticoagulation, provided hormones are stopped before anticoagulation ends. Dose reductions to prophylactic levels during acute treatment are not recommended. Low-molecular-weight heparin (LMWH) remains the standard in pregnancy without routine anti-factor Xa monitoring. Direct-acting oral anticoagulants (DOACs) are not recommended during lactation, whereas warfarin or LMWH may be considered postpartum.
Why it matters
The review summarizes clinical practice approaches to mitigating heavy menstrual bleeding and selecting safe anticoagulant regimens during pregnancy and breastfeeding.
Limits
The abstract describes a narrative review with no systematic search criteria, meta-analytic pooling, sample size counts, or primary comparative trial data. Specific effect sizes and confidence intervals are not reported.
Cited by
- supports Menstrual blood clots that are the size of a quarter or larger are considered abnormal and indicative of excessive bleeding, whereas dime-sized clots can be within the normal physiological range.